Hypopara in the News
The latest research, clinical trials, treatment approvals, and advocacy news from around the hypoparathyroidism community — curated by Bari.
These articles are from external sources and are not written by Bari. They are shared for informational purposes to keep the hypopara community informed.
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting for Once-Weekly Canvuparatide
BioSpace
Based on feedback from the FDA, MBX Biosciences plans to advance once-weekly canvuparatide into a Phase 3 trial in Q3 2026. Canvuparatide could become the first once-weekly PTH replacement therapy for hypoparathyroidism.
At-home calcium testing device could have wide-ranging impact in health care
VCU News
Tralyte Health is commercializing VCU professor Xuewei Wang's portable, at-home calcium monitoring device for hypoparathyroidism patients. Described as "a glucose monitor, but for calcium," the fingerstick-based system delivers results in about 15 minutes. The platform technology can be adapted for other electrolytes including potassium, sodium, and magnesium.
An at-home calcium tester is in development — and I'm celebrating!
Hypoparathyroidism News
Tralyte Health hopes to begin clinical testing on a portable at-home calcium monitoring device in 2027. The device would be a game-changer for hypopara patients who currently rely on laboratory blood draws with delayed results.
New Treatments for Hypoparathyroidism
Healthgrades
Overview of new treatments including FDA-approved palopegteriparatide (Yorvipath), the first once-daily injection specifically approved for hypoparathyroidism, plus emerging research in the treatment pipeline.
FDA approval of Palopegteriparatide as a promising orphan drug
PMC / National Library of Medicine
Comprehensive review of the FDA approval of Yorvipath (palopegteriparatide) as an orphan drug for hypoparathyroidism. This approval marks a critical milestone in endocrine therapeutics and offers renewed hope for patients.
A new trial for Allotransplantation: Parathyroid Allotransplant for Treatment of Hypoparathyroidism (PATTH)
Hypoparathyroidism Association
A new clinical trial is studying whether transplanting parathyroid tissue into the forearm can help hypoparathyroidism patients achieve sustained parathyroid hormone levels and reduce dependence on calcium and vitamin D supplements.
ESE announces Revised Clinical Practice Guideline for Treatment of Chronic Hypoparathyroidism in Adults
European Society of Endocrinology
The European Society of Endocrinology published updated clinical practice guidelines for treating chronic hypoparathyroidism in adults, reflecting new evidence and treatment options including PTH replacement therapy.
3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon PTH (Palopegteriparatide)
Ascendis Pharma
Long-term renal safety data from the TransCon PTH (palopegteriparatide) clinical program shared at Kidney Week 2025, demonstrating sustained kidney health outcomes over three years of treatment.
Could a New Pharmacological Treatment Provide Hope for Hypoparathyroidism Patients?
Endocrine News
In-depth follow-up on the FDA approval of palopegteriparatide for adults with hypoparathyroidism, exploring what this new pharmacological treatment means for patients and the future of hypopara care.
Encaleret Showed PTH-Independent Normalization of Blood and Urine Calcium in Phase 2 Study
BridgeBio Pharma
Phase 2 results show encaleret may help normalize blood and urine calcium in patients with chronic hypoparathyroidism without stimulating PTH — a first-in-class oral approach that works differently from PTH replacement.
Enrollment begins in natural history study of hypoparathyroidism
Hypoparathyroidism News
Coverage of the SHINE natural history study at Columbia University, including Bari Vapnek's perspective on why understanding long-term complications is critical for informed treatment decisions.
"With new treatment options on the horizon, understanding the long-term complications of hypoparathyroidism can help both physicians and patients make informed decisions about their care pathways."— Bari Vapnek
The Hypoparathyroidism Association Announces Patient Enrollment in First Prospective Natural History Study
GlobeNewswire
The Hypoparathyroidism Association announced enrollment in the SHINE study (NCT05793853) at Columbia University, led by Dr. Mishaela Rubin and sponsored by the FDA's Office of Orphan Products Development. The first-of-its-kind natural history study will follow 94 adults for three years to understand long-term complications.
"This study is particularly important to the hypoparathyroidism community as it underscores the needed paradigm shift surrounding treatment and understanding of the condition."— Bari Vapnek
Spotlight: Tralyte Health
Tralyte Health is developing a portable, at-home calcium monitoring device — described as "a glucose monitor, but for calcium." Based on research by Dr. Xuewei Wang at Virginia Commonwealth University, the fingerstick-based system could deliver calcium readings in about 15 minutes. Clinical testing is planned for 2027.
Visit Tralyte HealthKnow of a News Article?
If you've seen a news article about hypoparathyroidism that should be featured here, let Bari know!
Send to Bari